KRAS and cancer: We did not analyze the mechanisms underlying EZH2 overexpression in our tumor cohort, but there is evidence from the literature that NF-kB, MUC1-C, KRAS, MEK-ERK and PI3K-AKT signaling might cause significant EZH2 up regulation in human cancers [34–36].